HRP20171731T1 - (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A - Google Patents
(TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A Download PDFInfo
- Publication number
- HRP20171731T1 HRP20171731T1 HRP20171731TT HRP20171731T HRP20171731T1 HR P20171731 T1 HRP20171731 T1 HR P20171731T1 HR P20171731T T HRP20171731T T HR P20171731TT HR P20171731 T HRP20171731 T HR P20171731T HR P20171731 T1 HRP20171731 T1 HR P20171731T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- benzoxazepin
- thieno
- piperazin
- compounds
- Prior art date
Links
- -1 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS Chemical class 0.000 title 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 title 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000003840 hydrochlorides Chemical group 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (7)
1. Spoj, naznačen time što je spoj formule
[image]
,
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je HCl sol.
3. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, u kombinaciji s najmanje jednom farmaceutski prihvatljivom podlogom, razrjeđivačem ili pomoćnom tvari.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
5. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju nesanice.
6. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, ili njegova farmaceutski prihvatljiva sol, naznačen time što je za nesanicu karakteristična poteškoća u počinjanju spavanja ili održavanju spavanja ili oboje.
7. Spoj, naznačen time što je namijenjen upotrebi u skladu s bilo patentnim zahtjevom 5 ili 6, kod čovjeka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361752203P | 2013-01-14 | 2013-01-14 | |
| EP14701636.4A EP2943498B1 (en) | 2013-01-14 | 2014-01-08 | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists |
| PCT/US2014/010577 WO2014110065A1 (en) | 2013-01-14 | 2014-01-08 | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171731T1 true HRP20171731T1 (hr) | 2017-12-29 |
Family
ID=50023875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171731TT HRP20171731T1 (hr) | 2013-01-14 | 2017-11-13 | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9562057B2 (hr) |
| EP (1) | EP2943498B1 (hr) |
| JP (1) | JP6100400B2 (hr) |
| KR (1) | KR101735458B1 (hr) |
| CN (1) | CN104955827B (hr) |
| AU (1) | AU2014205616B2 (hr) |
| BR (1) | BR112015015491A8 (hr) |
| CA (1) | CA2893106C (hr) |
| CY (1) | CY1119517T1 (hr) |
| DK (1) | DK2943498T3 (hr) |
| EA (1) | EA026328B1 (hr) |
| ES (1) | ES2647523T3 (hr) |
| HR (1) | HRP20171731T1 (hr) |
| HU (1) | HUE037363T2 (hr) |
| LT (1) | LT2943498T (hr) |
| ME (1) | ME02898B (hr) |
| MX (1) | MX365594B (hr) |
| NO (1) | NO2971205T3 (hr) |
| PL (1) | PL2943498T3 (hr) |
| PT (1) | PT2943498T (hr) |
| RS (1) | RS56538B1 (hr) |
| SA (1) | SA515360750B1 (hr) |
| SI (1) | SI2943498T1 (hr) |
| WO (1) | WO2014110065A1 (hr) |
| ZA (1) | ZA201504041B (hr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602124A (en) * | 1994-12-12 | 1997-02-11 | Allelix Biopharmaceuticals, Inc. | 5-HT2 receptor ligands |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| JP2007505106A (ja) * | 2003-09-09 | 2007-03-08 | イーライ リリー アンド カンパニー | アゼピン、オキサゼピン、およびチアゼピンの置換ピペラジン |
| US7807828B2 (en) * | 2005-08-11 | 2010-10-05 | Hypnion, Inc. | Olanzapine analogs and methods of use thereof |
| AR084867A1 (es) * | 2011-02-07 | 2013-07-10 | Lilly Co Eli | Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual |
| AU2012283035B2 (en) * | 2011-07-08 | 2015-07-30 | Eli Lilly & Company | (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists |
| ES2650225T3 (es) * | 2011-08-30 | 2018-01-17 | Eli Lilly And Company | Compuestos (Tieno[2,3-b][1,5]benzoxazepin-4-il)piperazin-1-ilo con doble actividad como agonistas inversos de H1/antagonistas de 5-HT2A |
-
2014
- 2014-01-08 JP JP2015551850A patent/JP6100400B2/ja not_active Expired - Fee Related
- 2014-01-08 EA EA201591099A patent/EA026328B1/ru not_active IP Right Cessation
- 2014-01-08 CN CN201480004741.5A patent/CN104955827B/zh not_active Expired - Fee Related
- 2014-01-08 WO PCT/US2014/010577 patent/WO2014110065A1/en active Application Filing
- 2014-01-08 PT PT147016364T patent/PT2943498T/pt unknown
- 2014-01-08 ME MEP-2017-239A patent/ME02898B/me unknown
- 2014-01-08 AU AU2014205616A patent/AU2014205616B2/en not_active Ceased
- 2014-01-08 ES ES14701636.4T patent/ES2647523T3/es active Active
- 2014-01-08 US US14/758,023 patent/US9562057B2/en not_active Expired - Fee Related
- 2014-01-08 LT LTEP14701636.4T patent/LT2943498T/lt unknown
- 2014-01-08 RS RS20171134A patent/RS56538B1/sr unknown
- 2014-01-08 EP EP14701636.4A patent/EP2943498B1/en active Active
- 2014-01-08 SI SI201430378T patent/SI2943498T1/sl unknown
- 2014-01-08 BR BR112015015491A patent/BR112015015491A8/pt not_active IP Right Cessation
- 2014-01-08 PL PL14701636T patent/PL2943498T3/pl unknown
- 2014-01-08 KR KR1020157018420A patent/KR101735458B1/ko active IP Right Grant
- 2014-01-08 CA CA2893106A patent/CA2893106C/en not_active Expired - Fee Related
- 2014-01-08 MX MX2015008970A patent/MX365594B/es active IP Right Grant
- 2014-01-08 DK DK14701636.4T patent/DK2943498T3/en active
- 2014-01-08 HU HUE14701636A patent/HUE037363T2/hu unknown
- 2014-03-14 NO NO14777943A patent/NO2971205T3/no unknown
-
2015
- 2015-06-05 ZA ZA2015/04041A patent/ZA201504041B/en unknown
- 2015-07-13 SA SA515360750A patent/SA515360750B1/ar unknown
-
2017
- 2017-11-01 CY CY20171101141T patent/CY1119517T1/el unknown
- 2017-11-13 HR HRP20171731TT patent/HRP20171731T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171824T1 (hr) | (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| HRP20220766T1 (hr) | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| HRP20191523T1 (hr) | Paraziticidne kombinacije spirocikličkog izoksazolina | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| RS54873B1 (sr) | Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| CA2918938C (en) | Substituted aminopyrimidine compounds and methods of use | |
| CA2894892A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| CL2013003051A1 (es) | Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio | |
| MY174188A (en) | Heterocyclyl compounds | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| EP2847198A4 (en) | TETRAHYDRO [1,8] NAPHTHYRIDINE-SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS MMR AGONISTS AND IN THE TREATMENT OF DISEASE | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| PH12015501993B1 (en) | Pyrazole-amide compound and medicinal uses therefor | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| WO2015085909A8 (zh) | 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物 | |
| PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
| IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease |